Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Protein kinases are critical targets in cancer therapy, with numerous kinase inhibitors approved and in clinical trials.
• Previous work identified 4-aminoimidazole and 2-aminothiazole derivatives as Src family kinase (SFK) inhibitors.

Purpose of the Study:

• To optimize a library of 4-aminoimidazole derivatives to discover more potent SFK inhibitors.
• To evaluate the antiproliferative activity of novel compounds against cancer cell lines with Src hyperactivation.

Main Methods:

• Computational studies (docking) were performed to predict compound efficacy.
• Synthesis of optimized 4-aminoimidazole derivatives.
• In vitro screening for SFK inhibitory activity and cell-based antiproliferative assays.

Main Results:

• All synthesized compounds demonstrated SFK inhibitory activity in the nanomolar range, with 2- to 130-fold improvement over previous inhibitors.
• Compounds 4k and 4l exhibited significant antiproliferative effects on SH-SY5Y neuroblastoma cells.
• The novel compounds showed greater potency than dasatinib in neuroblastoma cell assays.

Conclusions:

• The optimized 4-aminoimidazole derivatives represent a potent new generation of SFK inhibitors.
• Compounds 4k and 4l show promise as novel therapeutic agents for neuroblastoma and potentially other Src-dependent cancers.